FS Development II registered with the SEC to offer 10 million units at $10 each to rapise $100 million in an IPO.
The new SPAC in the filing said it will focus on the biotechnology and life science infrastructure sectors.
FS Development II is led by Dr. Jim Tananbaum, president, CEO and director. He is the CEO of Foresite Capital, a U.S.-focused healthcare investment firm, which he founded in 2011.
The SPAC plans to list on the Nasdaq under FSII. Read more.
